What would test a broader healthspan claim?
LinkedIn caption
🧪 The GLP-1 conversation at ARDD 2026 raises a study-design question: what would test a broader healthspan claim?
SELECT demonstrated cardiovascular benefit for semaglutide in a defined population with existing cardiovascular disease and overweight or obesity, without diabetes. That evidence does not establish longevity benefits in healthy adults.
A broader claim needs its own prospective, controlled evidence: meaningful function, clinical outcomes, safety and enough follow-up for the question being asked. Exploratory aging-biology findings can help choose what to investigate. They cannot supply the answer in advance.
#ARDD2026 #GLP1 #Healthspan #ClinicalTrials
X caption
🧪 Semaglutide's cardiovascular evidence comes from a defined clinical population. A broader healthspan claim needs its own controlled studies of function, outcomes and safety. Exploratory aging signals help form hypotheses. #ARDD2026 #GLP1 #Healthspan
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
